TFF PHARMACEUTICALS I

TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVID

11 сен 2024 06:00:00 Источник Nasdaq GlobeNewswire

TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization

10 сен 2024 06:00:00 Источник Nasdaq GlobeNewswire

TFF Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

03 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire